Person · CIK 1751804

Laura Hamill

Director at Jazz Pharmaceuticals, Fate Therapeutics and Y-mAbs Therapeutics

Earlier: Pardes Biosciences, Scilex Holding, Anaptysbio, Acceleron Pharma and Gilead Sciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$0

Noticed on Form 144$1.3M

Bought on Form 4$0

Companies8

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Jazz Pharmaceuticals JAZZ	Ordinary Shares	Directly	6,832	Aug 31, 2026 · Filing · EDGAR
Fate Therapeutics FATE	Stock Option (Right to Buy) exercise $2.06, expires Jun 12, 2036, into Common Stock	Directly	175,800	Jun 12, 2026 · Filing · EDGAR
Scilex Holding	Nonstatutory Stock Option (right to buy) exercise $8.08, expires Jan 17, 2033, into Common Stock	Directly	250,000	Jan 17, 2023 · Filing · EDGAR
Anaptysbio	Stock Option (right to buy) exercise $23.23, expires Jan 5, 2033, into Common Stock	Directly	10,600	Jan 6, 2023 · Filing · EDGAR
Anaptysbio	Restricted Stock Unit into Common Stock	Directly	3,900	Jan 6, 2023 · Filing · EDGAR
Gilead Sciences	Common Stock	Directly	6,340	May 8, 2019 · Filing · EDGAR
Gilead Sciences	Non-qualified Stock Option (Right to Buy) exercise $68.75, expires Feb 6, 2029, into Common Stock	Directly	63,100	Feb 6, 2019 · Filing · EDGAR
Gilead Sciences	Restricted Stock Unit into Common Stock	Directly	46,435	Feb 6, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	—	$858K
Q3 2025	—	$418K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Jazz Pharmaceuticals JAZZ · Etrade Financial · No 10b5-1 plan stated · 2 notices
Aug 31, 2026	3,507 · ~$858K	Aug 31, 2026	Not sold yet	Filing · EDGAR
Aug 8, 2025	3,731 · ~$418K	Aug 8, 2025	Not sold within 90 days	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Jazz Pharmaceuticals JAZZ Director · filings 2024 to 2026 · $1.3M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 31, 2026	Shares withheld for tax or exercise price	−14	$244.06	$3K	8,524 direct	Filing · EDGAR
Aug 31, 2026	Shares withheld for tax or exercise price	−1,692	$241.39	$408K	6,832 direct	Filing · EDGAR
Aug 5, 2026	Grant or award from the company	+1,605			8,538 direct	Filing · EDGAR
Aug 8, 2025	Shares withheld for tax or exercise price	−1,805	$111.25	$201K	6,933 direct	Filing · EDGAR
Aug 7, 2025	Grant or award from the company	+3,507			8,738 direct	Filing · EDGAR
Aug 2, 2024	Grant or award from the company	+3,731			5,231 direct	Filing · EDGAR

Fate Therapeutics FATE Director · filings 2026 to 2026

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 12, 2026	Grant or award from the company Stock Option (Right to Buy)	+175,800			175,800 direct	Filing · EDGAR

Y-mAbs Therapeutics YMAB Director · filings 2020 to 2025

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 16, 2025	Tendered in a change of control	−5,825	$8.60	$50K	0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company	−25,080			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−27,000			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−11,000			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−16,000			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−13,950			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−14,545			0 direct	Filing · EDGAR
Sep 16, 2025	Returned to the company Employee Stock Option (right to buy)	−33,450			0 direct	Filing · EDGAR
Jun 30, 2025	Grant or award from the company	+25,080			30,905 direct	Filing · EDGAR
Jun 30, 2025	Grant or award from the company Employee Stock Option (right to buy)	+33,450			33,450 direct	Filing · EDGAR
Jun 11, 2024	Grant or award from the company	+3,495			5,825 direct	Filing · EDGAR
Jun 11, 2024	Grant or award from the company Employee Stock Option (right to buy)	+14,545			14,545 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company	+2,330			2,330 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company Employee Stock Option (right to buy)	+13,950			13,950 direct	Filing · EDGAR
Jul 15, 2022	Grant or award from the company Non-Employee Stock Option (right to buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 10, 2021	Grant or award from the company Non-Employee Stock Option (right to buy)	+16,000			16,000 direct	Filing · EDGAR
Jun 23, 2020	Grant or award from the company Non-Employee Stock Option (right to buy)	+32,000			32,000 direct	Filing · EDGAR

Pardes Biosciences Director · filings 2021 to 2023

Date	Transaction	Shares	Held after	Source
Aug 31, 2023	Returned to the company Stock Option (Right to Buy)	−37,500	0 direct	Filing · EDGAR
Aug 31, 2023	Returned to the company Stock Option (Right to Buy)	−70,390	0 direct	Filing · EDGAR
Aug 31, 2023	Returned to the company Stock Option (Right to Buy)	−75,000	0 direct	Filing · EDGAR
Aug 31, 2023	Returned to the company Stock Option (Right to Buy)	−37,500	0 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Stock Option (Right to Buy)	+37,500	37,500 direct	Filing · EDGAR
Jun 8, 2022	Grant or award from the company Stock Option (Right to Buy)	+37,500	37,500 direct	Filing · EDGAR
Dec 23, 2021	Grant or award from the company Stock Option (Right to Buy)	+75,000	75,000 direct	Filing · EDGAR

Scilex Holding Director · filings 2022 to 2023

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 17, 2023	Grant or award from the company Nonstatutory Stock Option (right to buy)	+250,000			250,000 direct	Filing · EDGAR

Anaptysbio Director · filings 2019 to 2023

Date	Transaction	Shares	Held after	Source
Jan 6, 2023	Grant or award from the company Stock Option (right to buy)	+10,600	10,600 direct	Filing · EDGAR
Jan 6, 2023	Grant or award from the company Restricted Stock Unit	+3,900	3,900 direct	Filing · EDGAR
Feb 10, 2022	Grant or award from the company Stock Option (right to buy)	+9,200	9,200 direct	Filing · EDGAR
Feb 10, 2021	Grant or award from the company Stock Option (right to buy)	+11,000	11,000 direct	Filing · EDGAR
Feb 12, 2020	Grant or award from the company Director Stock Option (Right to Buy)	+11,000	11,000 direct	Filing · EDGAR
Sep 24, 2019	Grant or award from the company Director Stock Option (Rigth to Buy)	+6,000	6,000 direct	Filing · EDGAR
Sep 24, 2019	Grant or award from the company Director Stock Option (Right to Buy)	+2,268	2,268 direct	Filing · EDGAR

Acceleron Pharma Director · filings 2020 to 2021

Date	Transaction	Shares	Held after	Source
Nov 19, 2021	Tendered in a change of control	−474	0 direct	Filing · EDGAR
Nov 19, 2021	Returned to the company Option to Purchase Common Stock	−9,339	0 direct	Filing · EDGAR
Nov 19, 2021	Returned to the company Option to Purchase Common Stock	−941	0 direct	Filing · EDGAR
Jan 29, 2021	Grant or award from the company	+474	474 direct	Filing · EDGAR
Jan 29, 2021	Grant or award from the company Option to Purchase Common Stock	+941	941 direct	Filing · EDGAR
Sep 15, 2020	Grant or award from the company Option to Purchase Common Stock	+9,339	9,339 direct	Filing · EDGAR

Gilead Sciences EVP, Worldwide Commercial Ops · filings 2018 to 2019

Date	Transaction	Shares	Price	Value	Held after	Source
May 8, 2019	Grant or award from the company	+9,840			9,840 direct	Filing · EDGAR
May 8, 2019	Shares withheld for tax or exercise price	−3,500	$66.07	$231K	6,340 direct	Filing · EDGAR
Feb 6, 2019	Grant or award from the company Non-qualified Stock Option (Right to Buy)	+63,100			63,100 direct	Filing · EDGAR
Feb 6, 2019	Grant or award from the company Restricted Stock Unit	+13,640			46,435 direct	Filing · EDGAR
Oct 7, 2018	Grant or award from the company Non-qualified Stock Option (Right to Buy)	+87,680			87,680 direct	Filing · EDGAR
Oct 7, 2018	Grant or award from the company Restricted Stock Unit	+32,795			32,795 direct	Filing · EDGAR

All 38 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 2, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Aug 31, 2026	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Aug 7, 2026	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 15, 2026	Form 4	Fate Therapeutics FATE	Filing · EDGAR
Jun 15, 2026	Form 3	Fate Therapeutics FATE	Filing · EDGAR
Sep 19, 2025	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Aug 11, 2025	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Aug 8, 2025	Form 144	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jul 2, 2025	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Aug 6, 2024	Form 4	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jul 30, 2024	Form 3	Jazz Pharmaceuticals JAZZ	Filing · EDGAR
Jun 13, 2024	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Aug 31, 2023	Form 4	Pardes Biosciences	Filing · EDGAR
Jun 9, 2023	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Jun 2, 2023	Form 4	Pardes Biosciences	Filing · EDGAR
Jan 17, 2023	Form 4	Scilex Holding	Filing · EDGAR
Jan 10, 2023	Form 4	Anaptysbio	Filing · EDGAR
Nov 15, 2022	Form 3	Scilex Holding	Filing · EDGAR
Jul 19, 2022	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Jun 10, 2022	Form 4	Pardes Biosciences	Filing · EDGAR
Feb 14, 2022	Form 4	Anaptysbio	Filing · EDGAR
Dec 28, 2021	Form 4	Pardes Biosciences	Filing · EDGAR
Dec 27, 2021	Form 3	Pardes Biosciences	Filing · EDGAR
Nov 22, 2021	Form 4	Acceleron Pharma	Filing · EDGAR
Jun 14, 2021	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Feb 12, 2021	Form 4	Anaptysbio	Filing · EDGAR
Feb 2, 2021	Form 4	Acceleron Pharma	Filing · EDGAR
Sep 17, 2020	Form 4	Acceleron Pharma	Filing · EDGAR
Sep 17, 2020	Form 3	Acceleron Pharma	Filing · EDGAR
Jun 24, 2020	Form 4	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Jun 18, 2020	Form 3	Y-mAbs Therapeutics YMAB	Filing · EDGAR
Feb 13, 2020	Form 4	Anaptysbio	Filing · EDGAR
Sep 26, 2019	Form 4	Anaptysbio	Filing · EDGAR
Sep 26, 2019	Form 3	Anaptysbio	Filing · EDGAR
May 10, 2019	Form 4	Gilead Sciences	Filing · EDGAR
Feb 8, 2019	Form 4	Gilead Sciences	Filing · EDGAR
Oct 9, 2018	Form 4	Gilead Sciences	Filing · EDGAR
Sep 18, 2018	Form 3	Gilead Sciences	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 1:47 AM ET. The filing on SEC.gov is the record.